The Chemours Company (CC)
NYSE: CC · Real-Time Price · USD
15.28
+0.04 (0.26%)
Aug 13, 2026, 4:00 PM EDT - Market closed
The Chemours Company Revenue
The Chemours Company had revenue of $1.59B in the quarter ending June 30, 2026, a decrease of -1.49%. This brings the company's revenue in the last twelve months to $5.80B, down -0.91% year-over-year. In the year 2025, The Chemours Company had annual revenue of $5.81B with 0.45% growth.
Revenue (ttm)
$5.80B
Revenue Growth
-0.91%
P/S Ratio
0.39
Revenue / Employee
$1,017,018
Employees
5,700
Market Cap
2.29B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.81B | 26.00M | 0.45% |
| Dec 31, 2024 | 5.78B | -296.00M | -4.87% |
| Dec 31, 2023 | 6.08B | -753.00M | -11.02% |
| Dec 31, 2022 | 6.83B | 486.00M | 7.66% |
| Dec 31, 2021 | 6.35B | 1.38B | 27.69% |
| Dec 31, 2020 | 4.97B | -557.00M | -10.08% |
| Dec 31, 2019 | 5.53B | -1.11B | -16.75% |
| Dec 31, 2018 | 6.64B | 455.00M | 7.36% |
| Dec 31, 2017 | 6.18B | 783.00M | 14.50% |
| Dec 31, 2016 | 5.40B | -317.00M | -5.54% |
| Dec 31, 2015 | 5.72B | -715.00M | -11.12% |
| Dec 31, 2014 | 6.43B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Calumet | 4.59B |
| H.B. Fuller Company | 3.51B |
| Stepan Company | 2.43B |
| Minerals Technologies | 2.15B |
| Quaker Chemical | 1.98B |
| Innospec | 1.84B |
| Ashland | 1.84B |
| Ingevity | 1.16B |
CC News
- 3 days ago - Chemours price target lowered to $18 from $21 at Morgan Stanley - TheFly
- 3 days ago - Chemours price target lowered to $18 from $21 at Morgan Stanley - TheFly
- 3 days ago - Chemours Launches Opteon™ ZE and Opteon™ 515B Refrigerants for Chiller Applications Powering Data Centers, Commercial Buildings, and Other Mission Critical Environments - PRNewsWire
- 3 days ago - Chemours downgraded to Neutral from Buy at UBS - TheFly
- 5 days ago - New Jersey's $2.5 billion 'forever chemicals' settlements with DuPont, 3M, others win court approval - Reuters
- 7 days ago - Chemours price target lowered to $24 from $30 at Truist - TheFly
- 7 days ago - Chemours price target lowered to $22 from $26 at RBC Capital - TheFly
- 8 days ago - The Chemours Company Earnings Call Transcript: Q2 2026 - Transcripts